Cargando…

Understanding Superiority, Noninferiority, and Equivalence for Clinical Trials

Randomized control trialsare the gold standard for testing the efficacy of new interventions. Historically, superiority trials were methods of choice as reference (standard) interventions were not established for many disease conditions. However currently, reference interventions are available for m...

Descripción completa

Detalles Bibliográficos
Autores principales: Kishore, Kamal, Mahajan, Rahul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7734976/
https://www.ncbi.nlm.nih.gov/pubmed/33344335
http://dx.doi.org/10.4103/idoj.IDOJ_130_20
_version_ 1783622574417117184
author Kishore, Kamal
Mahajan, Rahul
author_facet Kishore, Kamal
Mahajan, Rahul
author_sort Kishore, Kamal
collection PubMed
description Randomized control trialsare the gold standard for testing the efficacy of new interventions. Historically, superiority trials were methods of choice as reference (standard) interventions were not established for many disease conditions. However currently, reference interventions are available for most of adverse conditions. Despite this, many investigators are using superiority trials in comparison to more suitable noninferiority and equivalence trials. The application of noninferiority and equivalence trials is on the rise, but by and large, these trials are poorly understood, ill-conceived, inappropriately analyzed, and reported and misinterpreted.
format Online
Article
Text
id pubmed-7734976
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Wolters Kluwer - Medknow
record_format MEDLINE/PubMed
spelling pubmed-77349762020-12-18 Understanding Superiority, Noninferiority, and Equivalence for Clinical Trials Kishore, Kamal Mahajan, Rahul Indian Dermatol Online J Review Article Randomized control trialsare the gold standard for testing the efficacy of new interventions. Historically, superiority trials were methods of choice as reference (standard) interventions were not established for many disease conditions. However currently, reference interventions are available for most of adverse conditions. Despite this, many investigators are using superiority trials in comparison to more suitable noninferiority and equivalence trials. The application of noninferiority and equivalence trials is on the rise, but by and large, these trials are poorly understood, ill-conceived, inappropriately analyzed, and reported and misinterpreted. Wolters Kluwer - Medknow 2020-09-19 /pmc/articles/PMC7734976/ /pubmed/33344335 http://dx.doi.org/10.4103/idoj.IDOJ_130_20 Text en Copyright: © 2020 Indian Dermatology Online Journal http://creativecommons.org/licenses/by-nc-sa/4.0 This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle Review Article
Kishore, Kamal
Mahajan, Rahul
Understanding Superiority, Noninferiority, and Equivalence for Clinical Trials
title Understanding Superiority, Noninferiority, and Equivalence for Clinical Trials
title_full Understanding Superiority, Noninferiority, and Equivalence for Clinical Trials
title_fullStr Understanding Superiority, Noninferiority, and Equivalence for Clinical Trials
title_full_unstemmed Understanding Superiority, Noninferiority, and Equivalence for Clinical Trials
title_short Understanding Superiority, Noninferiority, and Equivalence for Clinical Trials
title_sort understanding superiority, noninferiority, and equivalence for clinical trials
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7734976/
https://www.ncbi.nlm.nih.gov/pubmed/33344335
http://dx.doi.org/10.4103/idoj.IDOJ_130_20
work_keys_str_mv AT kishorekamal understandingsuperioritynoninferiorityandequivalenceforclinicaltrials
AT mahajanrahul understandingsuperioritynoninferiorityandequivalenceforclinicaltrials